DK0970121T3 - Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose - Google Patents

Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose

Info

Publication number
DK0970121T3
DK0970121T3 DK98914725T DK98914725T DK0970121T3 DK 0970121 T3 DK0970121 T3 DK 0970121T3 DK 98914725 T DK98914725 T DK 98914725T DK 98914725 T DK98914725 T DK 98914725T DK 0970121 T3 DK0970121 T3 DK 0970121T3
Authority
DK
Denmark
Prior art keywords
mbp
residues
levels
amino acid
synthetic peptides
Prior art date
Application number
DK98914725T
Other languages
Danish (da)
English (en)
Inventor
Kenneth G Warren
Ingrid Catz
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Application granted granted Critical
Publication of DK0970121T3 publication Critical patent/DK0970121T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK98914725T 1997-04-04 1998-04-03 Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose DK0970121T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2201841A CA2201841C (en) 1997-04-04 1997-04-04 Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
PCT/CA1998/000290 WO1998045327A1 (en) 1997-04-04 1998-04-03 Peptide fragments of myelin basic protein, their pharmaceutical compositions and their use in treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK0970121T3 true DK0970121T3 (da) 2008-10-20

Family

ID=4160340

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98914725T DK0970121T3 (da) 1997-04-04 1998-04-03 Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose
DK03022727T DK1394178T3 (da) 1997-04-04 1998-04-03 Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03022727T DK1394178T3 (da) 1997-04-04 1998-04-03 Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment

Country Status (20)

Country Link
EP (2) EP1394178B1 (de)
JP (1) JP4173557B2 (de)
AT (2) ATE400582T1 (de)
AU (1) AU751303B2 (de)
CA (2) CA2494338C (de)
CY (2) CY1107445T1 (de)
CZ (1) CZ299535B6 (de)
DE (2) DE69839163T2 (de)
DK (2) DK0970121T3 (de)
ES (2) ES2307317T3 (de)
HU (1) HU226768B1 (de)
NO (1) NO325018B1 (de)
NZ (1) NZ338091A (de)
PL (1) PL191965B1 (de)
PT (2) PT1394178E (de)
RO (1) RO119303B1 (de)
RU (1) RU2198893C2 (de)
SK (1) SK285815B6 (de)
UA (1) UA60331C2 (de)
WO (1) WO1998045327A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541106A (zh) 2001-06-11 2004-10-27 转新疗法公司 用维生素b12和治疗剂联合治疗病毒性、增殖性和炎性疾病的方法
RU2261713C1 (ru) * 2004-04-27 2005-10-10 Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" Способ лечения тяжелой формы острого оптического неврита у пациентов с рассеянным склерозом
JP5709876B2 (ja) 2009-10-12 2015-04-30 ライフバイオ ラボラトリーズ エルエルシーＬＩＦＥＢｉｏ ＬＡＢＯＲＡＴＯＲＩＥＳ ＬＬＣ 多発性硬化症治療用組成物
RU2646817C1 (ru) * 2016-12-27 2018-03-07 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид из состава тяжелой цепи иммуноглобулина человека, пригодный для лечения рассеянного склероза

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021611C1 (ru) * 1991-04-19 1994-10-15 Михайленко Анатолий Андреевич Способ диагностики рассеянного склероза
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
DE69331501T2 (de) * 1992-04-09 2002-08-29 Autoimmune, Inc. Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
CZ122697A3 (en) * 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
SK132999A3 (en) 2000-06-12
JP2001518885A (ja) 2001-10-16
NZ338091A (en) 2001-10-26
EP0970121B1 (de) 2008-07-09
PL191965B1 (pl) 2006-07-31
CZ299535B6 (cs) 2008-08-27
ES2307317T3 (es) 2008-11-16
DE69839163D1 (de) 2008-04-03
EP1394178B1 (de) 2008-02-20
DK1394178T3 (da) 2008-05-26
HK1063805A1 (en) 2005-01-14
NO994806L (no) 1999-12-06
SK285815B6 (sk) 2007-08-02
PT970121E (pt) 2008-09-22
RU2198893C2 (ru) 2003-02-20
ATE400582T1 (de) 2008-07-15
PL336085A1 (en) 2000-06-05
EP1394178A1 (de) 2004-03-03
ES2299657T3 (es) 2008-06-01
ATE386941T1 (de) 2008-03-15
RO119303B1 (ro) 2004-07-30
CY1107445T1 (el) 2012-12-19
CZ9903464A3 (cs) 2000-11-15
UA60331C2 (uk) 2003-10-15
CY1108239T1 (el) 2014-02-12
HUP0000812A3 (en) 2000-10-30
HUP0000812A2 (hu) 2000-09-28
EP0970121A1 (de) 2000-01-12
NO325018B1 (no) 2008-01-14
NO994806D0 (no) 1999-10-01
CA2494338A1 (en) 1998-10-04
DE69839163T2 (de) 2009-02-12
CA2201841C (en) 2010-01-26
AU751303B2 (en) 2002-08-15
PT1394178E (pt) 2008-04-15
JP4173557B2 (ja) 2008-10-29
HU226768B1 (en) 2009-09-28
DE69839694D1 (de) 2008-08-21
CA2201841A1 (en) 1998-10-04
AU6913098A (en) 1998-10-30
WO1998045327A1 (en) 1998-10-15
CA2494338C (en) 2007-07-17

Similar Documents

Publication Publication Date Title
NZ293910A (en) Peptides useful in immunoregulation of antibodies to human myelin basic protein, pharmaceutical compositions and method of treatment
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
MD1443F1 (en) Copolymer-1 fraction, process for preparation thereof and compositions on base thereof for cerebrospinal sclerosis treatment
AU2750092A (en) Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
CY1108239T1 (el) Θραυσματα πεπτιδιου της βασικης πρωτεϊνης της μυελινης, οι φαρμακευτικες τους συνθεσεις και η χρηση τους στη θεραπεια της σκληρυνσης κατα πλακας
NZ335835A (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
EP0342015A3 (de) Peptide, deren Benutzung und sie enthaltende pharmazeutische Zusammensetzungen